Therapy of serious infections with cefamandole

Area of Science:

• Infectious Diseases
• Pharmacology
• Bacteriology

Background:

• Serious bacterial infections pose significant treatment challenges.
• The emergence of antibiotic resistance necessitates evaluating new therapeutic agents.
• Cefamandole is a cephalosporin antibiotic with activity against various bacteria.

Purpose of the Study:

• To evaluate the efficacy and safety of cefamandole in treating serious bacterial infections.
• To assess the bacteriologic response and clinical outcomes in a patient cohort.
• To determine the drug's tolerability, particularly in patients with a history of penicillin allergy.

Main Methods:

• A clinical study involving 44 patients diagnosed with serious bacterial infections.
• Patients received cefamandole at a dosage of 1-2 g every four to six hours.
• Outcomes including clinical cure, bacteriologic response, and adverse events were recorded.

Main Results:

• An overall bacteriologic response rate of 80% was observed.
• 32 patients were cured, and 6 were markedly improved; 6 patients experienced treatment failure.
• Superinfections with cephalothin-resistant microorganisms were noted in three of the six failures.
• Bloodstream infections (bacteremia) were sterilized in 12 out of 13 patients.
• Gram-negative bacillary infections showed a response in 10 out of 14 patients.
• Fifteen patients with a history of penicillin allergy tolerated cefamandole without serious adverse reactions, though skin rash occurred in some.

Conclusions:

• Cefamandole demonstrates significant efficacy in treating serious bacterial infections, including bacteremia and gram-negative infections.
• The antibiotic is generally well-tolerated, with a favorable safety profile even in patients with penicillin allergy.
• Emergence of resistance is a factor to consider, highlighting the importance of susceptibility testing.